| Nov 19 |
Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab’s CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis
|
| Nov 14 |
Chemomab Therapeutics GAAP EPS of -$0.01 beats by $0.05
|
| Nov 14 |
Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
|
| Nov 14 |
Earnings Scheduled For November 14, 2024
|
| Oct 30 |
Chemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update
|
| Oct 15 |
Chemomab Therapeutics Announces Late-Breaking Oral Presentation of CM-101 Phase 2 Results in Primary Sclerosing Cholangitis at AASLD The Liver Meeting® 2024
|
| Oct 1 |
Chemomab Therapeutics to Present at October 2024 Investor Conferences
|
| Aug 28 |
Chemomab Therapeutics to Present at September 2024 Investor Conferences
|
| Aug 21 |
Chemomab Therapeutics GAAP EPS of -$0.01
|
| Aug 21 |
Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
|
